Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for ...

The FDA typically follows the recommendations of its advisory panels but is not required to do so. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

A new blood test that could help doctors identify whether a patient has Alzheimer’s disease was cleared by the FDA last week.

The test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but is designed to rule out the ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks to invest in before they split next. On September 9, Eli Lilly and Company launched a new global campaign titled “Brain Health Matters” to ...

INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

The FDA has granted 510(k) clearance to a blood-based biomarker test indicated for early detection of Alzheimer’s disease and other causes of cognitive decline within a primary care setting, according ...

Eli Lilly said it received marketing authorization from the European Commission for Kisunla, a treatment for early symptomatic Alzheimer's disease. Kisunla showed in a phase 3 trial that it can ...

The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...